Publication at First Faculty of Medicine, Third Faculty of Medicine |
2020
Abstract
Atopic dermatitis is an inflammatory skin condition affecting 1 to 20% of the population worldwide. Ocular comorbidities like conjunctivitis, keratitis and keratoconus have been more often described in atopic patients.
Aproximately 20% need systemic therapy due to the severity of their disease (moderate to severe). Dupilumab is a human anti-interleukin-4 receptor-a antibody, approved as the first biologic treatment for atopic dermatitis.